Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WEIGHTAIN is a proprietary nutraceutical satiety ingredient developed by Ingredion Incorporated for weight management. It is a co-processed composite formulation consisting of a viscous dietary fiber (specifically the hydrocolloid guar gum) and whole-grain high-amylose corn flour, which serves as a rich source of type 1 and type 2 resistant starch (HAM-RS). The ingredient works through multiple biological mechanisms: the viscous fiber component increases gastrointestinal viscosity to slow gastric emptying and prolong nutrient absorption, while the resistant starch undergoes fermentation by colonic microbiota to produce short-chain fatty acids (SCFAs). These SCFAs activate G-protein coupled receptors, including free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3), triggering the release of anorexigenic hormones such as glucagon-like peptide 1 (GLP-1) and peptide YY (PYY). These hormones signal satiety to the brain and suppress appetite. WEIGHTAIN is designed to be incorporated into various food products such as bars, muffins, smoothies, and baked goods to help manage obesity and overweight conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WEIGHTAIN.